Please login to the form below

Not currently logged in
Email:
Password:

Catalent promotes Sharon Johnson within new organisation

She will be its senior VP of global quality and regulatory affairs

edit-Catalent-Sharon-JohnsonCatalent Pharma Solutions has appointed Sharon Johnson as senior VP of global quality and regulatory of its new quality, product development and regulatory affairs organisation.

Johnson will oversee the function that includes over 1,500 scientists, quality professionals and regulatory affairs experts. 

Prior to her promotion, Johnson held the same role at Catalent since 2009, overseeing the roll out of the company's global quality management system to over 20 sites globally.

She has over 30 years of experience in the pharma industry, including API and multiple dosages forms, discovery and launch of NCEs and life cycle management. Prior to joining Catalent, Johnson served as VP of quality for GE Healthcare's medical diagnostic division.

Commenting on the new organisation, Johnson said: “The overall goal of the quality, product development and regulatory affairs organisation will be to drive excellence and reliability across all of the products that we make and deliver.

“Our customer promise is not only to provide a reliable supply of their current, on going products but to deliver new products with the same rigorous commitment to excellence.”

Catalent, which is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has recently formed its quality, product development and regulatory affairs organisation.

18th March 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...